Literature DB >> 20977930

Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients.

C Moreau1, P Gosset, J Kluza, V Brunaud-Danel, P Lassalle, P Marchetti, L Defebvre, A Destée, D Devos.   

Abstract

The clinical course of the degenerative motor neuron disorder amyotrophic lateral sclerosis (ALS) is closely related to hypoxia. The normal response to hypoxia involves two pathways in particular: the hypoxia inducible factor 1α (HIF-1α) pathway (which notably controls the synthesis of vascular endothelial growth factor (VEGF)) and the nuclear factor kappa B (NF-κb) pathway (responsible for the production of inflammatory mediators, including prostaglandin E2 (PGE2)). Defects in VEGF gene expression are known to cause motor neuron degeneration in animal models. Circulating monocytes are precursors of the microglia, which are involved in the pathogenesis of ALS. To establish whether the HIF-1 and/or NF-κB pathways are deregulated during hypoxia in early-stage, sporadic ALS, we analyzed the response to acute (1 h) and prolonged (24 h) hypoxia in monocytes from ALS and healthy controls. We measured protein expression and mRNA transcription for VEGF, HIF-1, HIF-2, prolyl hydroxylases 1 and 2 (PHD-1 and -2, part of the HIF proteasome-dependent degradation pathway) and their modulation by PGE2. Our results showed that (i) the HIF-1 (but not HIF-2) and VEGF production induced by acute and prolonged hypoxia was selectively and markedly altered in ALS patients and (ii) this defect was not compensated for by PGE2 addition. Moreover, altered HIF-1α activation was associated with low levels of proteolysis by PHD-2 in cells from sporadic ALS patients (relative to controls). For the first time, we have demonstrated clinical and functional abnormalities in the HIF-1 pathway during hypoxia in monocytes from sporadic ALS patients.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977930     DOI: 10.1016/j.neuroscience.2010.10.040

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  14 in total

Review 1.  Hypoxia signaling in human health and diseases: implications and prospects for therapeutics.

Authors:  Zhen Luo; Mingfu Tian; Ge Yang; Qiaoru Tan; Yubing Chen; Geng Li; Qiwei Zhang; Yongkui Li; Pin Wan; Jianguo Wu
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

2.  Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions.

Authors:  Rohini Raman; Scott P Allen; Emily F Goodall; Shelley Kramer; Lize-Linde Ponger; Paul R Heath; Marta Milo; Hannah C Hollinger; Theresa Walsh; J Robin Highley; Simon Olpin; Christopher J McDermott; Pamela J Shaw; Janine Kirby
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

3.  Nocturnal hypoxia in ALS is related to cognitive dysfunction and can occur as clusters of desaturations.

Authors:  Su-Yeon Park; Sung-Min Kim; Jung-Joon Sung; Kyung-Min Lee; Kyung-Seok Park; Sang-Yun Kim; Hyun-woo Nam; Kwang-Woo Lee
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

Review 4.  Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy.

Authors:  Luis B Tovar-Y-Romo; Uri Nimrod Ramírez-Jarquín; Rafael Lazo-Gómez; Ricardo Tapia
Journal:  Front Cell Neurosci       Date:  2014-02-28       Impact factor: 5.505

Review 5.  Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.

Authors:  Ana Catarina Pronto-Laborinho; Susana Pinto; Mamede de Carvalho
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

Review 6.  RNA-Binding Proteins in the Regulation of miRNA Activity: A Focus on Neuronal Functions.

Authors:  Alessia Loffreda; Aurora Rigamonti; Silvia M L Barabino; Silvia C Lenzken
Journal:  Biomolecules       Date:  2015-09-30

7.  Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis.

Authors:  Satoru Tada; Tatsusada Okuno; Mikito Shimizu; Yoshiki Sakai; Hisae Sumi-Akamaru; Makoto Kinoshita; Kazuya Yamashita; Eri Sanda; Chi-Jing Choong; Akiko Namba; Tsutomu Sasaki; Toru Koda; Kazushiro Takata; Shigeru Miyagawa; Yoshiki Sawa; Yuji Nakatsuji; Hideki Mochizuki
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

Review 8.  Redox regulation in amyotrophic lateral sclerosis.

Authors:  Sonam Parakh; Damian M Spencer; Mark A Halloran; Kai Y Soo; Julie D Atkin
Journal:  Oxid Med Cell Longev       Date:  2013-02-25       Impact factor: 6.543

9.  Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1α and Nrf2.

Authors:  Diana Wiesner; Irma Merdian; Jan Lewerenz; Albert C Ludolph; Luc Dupuis; Anke Witting
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

Review 10.  The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis.

Authors:  Vedrana Tadic; Tino Prell; Janin Lautenschlaeger; Julian Grosskreutz
Journal:  Front Cell Neurosci       Date:  2014-05-30       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.